As per the research reports by MRFR, the global Precision Medicine Market Trends was valued USD 65.93 billion in 2021 and is expected to reach USD 157.46 Billion by 2030 at 11.9% CAGR during the forecast period 2022-2030. Precision medicine, also called personalized medicines, has been gaining traction worldwide as they allow the intrusion of patients in taking personal healthcare and offer more targeted therapies for patients that will offer lucrative opportunities over the review timeframe. The global Precision Medicine Market has witnessed massive growth due to advanced technological developments, more targeted therapies to the individuals, increasing prevalence of various genetic diseases, and the launch of numerous big data healthcare companies. However, the increased costs of diagnosis and strict regulations and standards can restrict the market's growth over the coming years.

Competitive Analysis

The global market for precision medicine has a strong and competitive landscape. The list of leading players in the precision medicine market includes companies such as Intomics A/S, GE Healthcare, ASURAGEN, Inc., ABBOTT LABORATORIES, Medtronic, Novartis, BIOBASE GmbH (Subsidiary), LABORATORY CORPORATION OF AMERICA HOLDINGS, CETICS Healthcare Technologies GmbH, bioMérieux SA, Teva Pharmaceutical Industries Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Randox Laboratories Ltd, Johnson & Johnson, Cepheid Inc., InnVentis, Intel Corporation, AB-Biotics SA, Caris Life Sciences, Quest Diagnostics Inc., Glaxosmithkline Plc (GSK), IBM, Molecular Health GmbH, and Precision for Medicine, HealthCore, Inc., Roche Holding AG-Br, Pfizer Inc, Qiagen, Almac Group, Ltd., and many others.

Segment Analysis

The global precision medicine market is divided into segments based on submarkets, therapeutics, region, and ecosystem players.

• Based on submarkets, the market is split into molecular diagnostics, targeted therapeutics, pharmacogenomics or PGX, companion diagnostics, biomarker-based tests, and many more.
• Based on therapeutics, the precision medicines market is split into infectious disease, central nervous system, cardiovascular disease or CVD, cancer or oncology, and others.
• Based on the ecosystem players, the precision medicine market is divided into pharmaceuticals and biotechnology companies, healthcare IT specialists or big data companies, clinical laboratories, diagnostics companies, and many more.

Regional Analysis

The global market for precision medicines is studied across five major regions: North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

As per the MRFR report, the North American region will likely dominate the precision medicines market globally over the review timeframe. The regional market's growth is attributed to the advanced gene mapping technologies and growing demand for personalized medicine.

The European regional market for precision medicines is likely to secure the second position globally over the coming years owing to the well-developed healthcare infrastructure and consistent technological advancements.

The growth of the precision medicines market for the Asia-Pacific region is being driven by the better healthcare infrastructure and increased disposable income.

Recent Developments

• January 2022—Caris Life Sciences®, the prominent company in molecular science and technology proactive in the development and delivery of innovative solutions to transform healthcare, and HotSpot Therapeutics, Inc., a biotechnology firm pioneering the discovery and development of high-quality allosteric therapies focusing on regulatory sites on proteins referred to as "natural hotspots," have announced a planned collaboration to develop precision medicine methods for HotSpot's emerging product portfolio. The partnership will primarily target two therapeutic programs.

• January 2022- a company translating genetic insights into new precision medicines, Maze Therapeutics, has announced a USD 190 million investment led by Matrix Capital Management with contribution from General Catalyst, Foresite Capital, Casdin Capital, a16z Bio+Health, NS Investments, Moore Strategic Ventures, City Hill Ventures, Terra Magnum Capital Partners, Driehaus Capital Management, Woodline Partners, and several others. Maze was introduced in 2019 and has generated two joint ventures and nine programs since then.

• January 2022 – a precision medicine firm looking for unlocking the proteome to advance innovations against otherwise undruggable disease-causing targets, Frontier Medicines Corporation has announced the first target to develop a small molecule inhibitor is developing into the lead production stage under the firm's global partnership with AbbVie. The worldwide partnership was founded in December 2020 to discover, develop, and commercialize a pipeline of the latest small molecule therapeutics against some high-interest, difficult-to-drug protein targets.

Related Report:

U.S. Direct Anterior Approach Market Research Report –Global Forecast to 2027    

 Flow Cytometry Market Research Report – Forecast to 2027

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013